ROLE OF ORAL HYPOGLYCEMIC THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

Даминова Л.Т, Садикова Д.Ш, Муминова C.У

Марказий Осиё эндокринологик журнали · 2024-yil

Annotatsiya

For patients with diabetes, one of the main therapeutic goals is to achieve target glycemic levels. In the presence of NAFLD, the attending physician is faced with some restrictions when choosing glucose-lowering therapy. The drugs, in addition to sufficient glucose-lowering activity, must be safe for the liver and not have hepatotoxicity. In addition, glucose-lowering drugs must have proven cardiovascular safety, since type 2 diabetes and NAFLD mutually aggravate not only each other’s course, but also significantly increase cardiovascular risk.

Maqola ma’lumotlari
MualliflarДаминова Л.Т, Садикова Д.Ш, Муминова C.У
JurnalМарказий Осиё эндокринологик журнали
Nashr sanasi2024-07-04
Jild4
Son1
TilRus

Kalit so‘zlar

сахарный диабет 2 типа, НАЖБП, сахароснижающие препараты, Type 2 diabetes, NAFLD, hypoglycemic drugs, Qandli diabet 2 turi, NAYJK, gipoglikemik preparatlar

Ilmiy soha

Марказий Осиё эндокринологик журнали jurnalidan boshqa maqolalar

Марказий Осиё эндокринологик журнали — barcha maqolalar